Navigation Links
Amilpar - Press Release
Date:1/12/2010

RIO DE JANEIRO, Jan. 12 /PRNewswire-FirstCall/ -- Amilpar (BOVESPA: AMIL3, Bloomberg: AMIL3 BZ and APAR < GO >; Reuters: AMIL3 SA), the largest managed care organization in Brazil, in accordance with CVM (Brazilian Securities and Exchange Commission) Instruction 358/02, informs that was approved in Board Meeting held today, the 1st Issuance of Debentures for public distribution with restricted selling efforts (according to CVM Instruction 476/09), with the objective of increase Company's cash position after the acquisition of Medial Saude S.A. control, under the following terms and conditions:

    Total Amount: R$ 300 million
    Term: 360 days, with the option of anticipating redemption after 180 days
    Remuneration: 109.75% of CDI (average interbank deposit rate in Brazil)
    Issuance: January 26, 2010
    Coordinators: Banco Itau BBA S.A. e HSBC CTVM S.A.

    To access the .pdf version, visit our website at www.amilpar.com.br/ir.

    IR Contacts:
    Investor Relations
    Phone.: +55 (21) 3805-1155
    E-mail: invest@amil.com.br
    www.amilpar.com.br/ir

SOURCE Amilpar

RELATED LINKS
http://www.amilpar.com.br/ir

'/>"/>

SOURCE Amilpar
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007
2. Amilpar Revenues Grow 28% in the First 9 Months of 2008 and 4.5% Over Previous Quarter
3. Amilpar - Notice to Shareholders - Distribution of Interest on Capital Stock
4. Amilpar - Revenues Increase by 26.5% and Adjusted Net Income Climbs 28.7% in 2008
5. Amilpar - Revenue Increases 13.4% and Medical Loss Ratio Falls in the First Quarter 2009
6. Amilpar - Operating Revenues Grew 9% in the Second Quarter and 11% in the First Half of 2009
7. Amilpar - Relevant Fact - Public Offer
8. Amilpar - Press Release - Commercial Papers
9. Amilpar - Relevant Fact
10. Amilpar - Distribution of Interest on Capital Stock
11. Amilpar - Revenues Grow 8% and Net Income Improves 28% in 3Q09
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... Youth Villages will participate in a partnership ... the feasibility of implementing a Pay for Success model ... their families. , Third Sector Capital Partners Inc. ran ... provided technical assistance throughout 2015 toward a Pay for ... awardees chosen by Third Sector. The organization’s work with ...
(Date:3/29/2015)... North American Seminars receives Texas Board ... Education Courses . , Utilizing Pilates to ... TPTA, approval # 56399TX      , The Interactive ... complex - 10.5 hours - Texas Board of Physical ... Treatment of the SI Joint - 10 hours - ...
(Date:3/28/2015)... Bellingham, WA (PRWEB) March 28, 2015 ... for athletes, recently announced the release of their new natural ... ounce and 3 ounce packages. Both options come with ... be purchased at RocketPure.com or on Amazon. Click ... product description states that the natural sunscreen is made with ...
(Date:3/28/2015)... Could genetic code determine someone’s coffee ... by researchers at the Harvard T.H. Chan School ... of the Coffee and Caffeine Genetics Consortium and ... fall, the study—one of several recent HSPH investigations of ... more than 120,000 regular coffee drinkers of European and ...
(Date:3/28/2015)... Take a bite of warm, gooey pepperoni pizza, ... into the stomach, ready to break down your meal. ... acids run amok, triggering a burning sensation in the ... 60 million Americans have heartburn at least once a ... how it can be stopped. , Heartburn or acid ...
Breaking Medicine News(10 mins):Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2
... Every Step Counts Organization in,association with Clear ... Park will continue its efforts to celebrate survivors ... host "Walk In,Her Shoes" 2008, a unique designer ... Louis and Atlanta. Designer shoes featured in "Walk ...
... CINCINNATI, Feb. 25 LCA-Vision Inc. (Nasdaq:,LCAV), a leading ... announced the opening of a LasikPlus vision center in ... in the United,States and the first LasikPlus vision center ... located in 33 states, serving 58 markets., Similar ...
... Participation in HIMSS Highlights Myriad Opportunities for Using Wireless ... to Improve Efficiency and Accuracy of Patient Care, ... leading,global provider of intelligent wireless LANs (WLANs) for enterprises ... Annual HIMSS,Conference & Exhibition, taking place February 24-28 in ...
... Healthcare Organizations Deliver Clinical ... Data Faster and Improve Productivity, ... provider of intelligent wireless LANs (WLANs) for enterprises and,service ... ) ( http://www.cardiacscience.com ), the leading provider of,cardiac monitoring, ...
... Increased Uptake of, CellCept Will Provide Effective Treatment ... ... WALTHAM, Mass., Feb. 25 Decision Resources, one of the,world,s ... that the entry and uptake of high-priced branded,agents will drive ...
... IQ for HealthVault Empowers Patients to Orchestrate Health ... ... Kryptiq, the leading provider,of next generation healthcare connectivity solutions, ... offices,and patients using Microsoft(R) HealthVault(TM), at the 2008 HIMSS,(Healthcare Information ...
Cached Medicine News:Health News:Shoe Therapy Helps Survivors Celebrate Life After Abuse 2Health News:LCA-Vision Announces the Opening of its 74th LasikPlus Vision Center in Des Moines, Iowa 2Health News:Colubris Demonstrates Wide-Ranging Mobility Solutions for Healthcare 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 3Health News:Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 3
(Date:3/27/2015)... BEIJING , March 27, 2015 ... the "Company") (NYSE: CCM ), a leading ... the largest network of radiotherapy and diagnostic imaging ... announced the signing of a purchase agreement under ... wholly owned subsidiary of the Company, agreed to ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... with a focus on Omega-3 therapies for cardiovascular disease ... it issued 763,752 common shares of the Corporation (the ... for the period of December 5 th , 2014 ... Convertible Notes that is due on or before April ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
Breaking Medicine Technology:Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
... 2011 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, ... the companies have begun enrolling patients in a ... (sorafenib) tablets in combination with the oral chemotherapeutic ... treatment of patients with advanced breast cancer. This ...
... OSAKA, Japan, February 23, 2011 Takeda Pharmaceutical ... Research & Development Center, Inc. U.S., submitted a ... and Drug Administration (FDA) for an investigational fixed-dose ... the treatment of hypertension, or high blood pressure. ...
Cached Medicine Technology:Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 2Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 3Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 4Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 5Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 6Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 7Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension 2Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension 3
... Clinical is an open platform for clinical diagnostic ... deck sizes of 75, 100, 150 and ... for your laboratory space and throughput requirements. Tecan ... to allow new applications and to evolve the ...
... maximum productivity, and proven reliability, Sorvall ... fully automatic cell washing and centrifugation ... 80-second wash cycle for stat testing, ... and standardized, reproducible procedures. High reliability, ...
Excellent all-around performance in digital format - MIC-D offers an exciting new way to observe the natural world. Multiple performance features provide new ways to enjoy microscope observation....
... model centrifuge. High throughput, refrigeration maintains ... with all windshield rotors, lifetime reproducibility, ... a remote personal computer or laboratory ... imbalance detection and shut down, armor ...
Medicine Products: